Venetoclax with dose-adjusted EPOCH-R as initial therapy for patients with aggressive B-cell lymphoma: a single-arm, multicentre, phase 1 studySarah C. Rutherford, John P. Leonard, Trisha Ali-Shaw et al.|The Lancet Haematology|2021Cited by 27
Phase I study of the Bcl-2 inhibitor venetoclax with DA-EPOCH-R as initial therapy for aggressive B-cell lymphomas.Sarah C. Rutherford, John P. Leonard, Jeremy S. Abramson et al.|Journal of Clinical Oncology|2020Cited by 8
A Phase I Study of Selinexor and R-ICE in Patients with Relapsed/Refractory Aggressive B-Cell LymphomasSarah C. Rutherford, Peter Martin, John N. Allan et al.|Blood|2020Cited by 8